AkesoFRA:4RY -4.29%54 Days Payable is 232.23 as of Dec. 2025, which is 75% below its 10-year median of 918.00. GuruFocus rates FRA:4RY with a GF Score™ of 54/100 and a GF Value™ of €15.78 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 705 Biotechnology companies, Akeso ranks better than 67.38% on this metric.
Akeso's average Accounts Payable for the
six
months ended in Dec. 2025 was €55.8 Mil. Akeso's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €43.8 Mil.
Hence, Akeso's Days Payable for the
six
months ended in Dec. 2025 was 232.23.
The historical rank and industry rank for Akeso's Days Payable or its related term are showing as below:
FRA:4RY'
s Days Payable Range Over the Past 10 Years
Min: 241.39 Med: 918 Max: 1840.99
Current: 248.83
During the past 8 years, Akeso's highest Days Payable was 1840.99. The lowest was 241.39. And the median was 918.00.
FRA:4RY's Days Payable is ranked better than 67.38% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs FRA:4RY: 248.83
Akeso's Days Payable
declined
from Dec. 2024 (358.31) to Dec. 2025 (232.23).
It may suggest that Akesoaccelerated paying its suppliers.
Akeso Days Payable Related Terms
Akeso Days Payable Historical Data
* Premium members only.
The historical data trend for Akeso's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4RY vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Akeso's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's Days Payable distribution charts can be found below:
* The bar in red indicates where Akeso's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Akeso's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso (FRA:4RY) has a Days Payable of 232.23 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akeso and its competitors. This is 75% below median its historical median of 918.00. Over the past decade, Akeso's Days Payable has ranged from 241.39 to 1,840.99. According to the industry distribution chart, Akeso ranks #230 out of 705 companies in the Biotechnology industry, placing it in the top 32.6%.
Is Akeso's Days Payable too high?
Akeso's current Days Payable of 232.23 is 75% below median its 10-year median of 918.00. Over the past 10 years, this metric has ranged from a low of 241.39 to a high of 1,840.99. The Biotechnology industry median Days Payable is 113.36. Akeso's value of 232.23 is 104.9% above this industry median. Based on the distribution chart, Akeso ranks #230 out of 705 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Akeso has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Akeso's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Akeso ranks #230 out of 705 companies for Days Payable. This puts Akeso in the upper half of its industry. The industry median Days Payable is 113.36. Akeso's value of 232.23 is 104.9% above this benchmark. Historically, Akeso's own Days Payable has ranged from 241.39 to 1,840.99 over the past decade. While the company's 10-year median is 918.00 vs. the industry median of 113.36, Akeso has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akeso's current Days Payable of 232.23 is 104.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akeso and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akeso's current Days Payable is 232.23, which is 75% below median its own 10-year median of 918.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Possible Value Trap. The stock's GF Value™ is €15.78, compared to a current price of €9.19 — trading 41.8% below its estimated fair value. The current Days Payable is 232.23, which is 75% below median its 10-year median of 918.00 and 104.9% above the Biotechnology industry median of 113.36. Akeso's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Akeso (FRA:4RY), the current Days Payable is 232.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akeso (FRA:4RY) Overvalued in 2026?
Based on GuruFocus' analysis, Akeso stock appears to be undervalued.
The current stock price of €9.19 is trading 41.8% below its estimated GF Value™ of €15.78.
GuruFocus considers Akeso to be Possible Value Trap.
Key valuation signals for FRA:4RY:
Days Payable: 232.23 (75% below median its 10-year median of 918.00)
GF Value™: €15.78 vs. price of €9.19 (41.8% below fair value)
Industry Position: 104.9% above the Biotechnology median (#230 of 705)
No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
54GF Score
Get the complete analysis for FRA:4RY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RY has been successfully added to your 
